Compass Therapeutics, Inc. Form 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K was filed by Compass Therapeutics, Inc. (NASDAQ: CMPX) on June 22, 2026. The report addresses corporate governance amendments approved by the Board of Directors on the same date.
Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report is a current report regarding corporate bylaws and does not contain financial statements or performance metrics.
Material Changes
The Board of Directors approved the adoption of the Second Amended and Restated Bylaws, effective June 22, 2026. The primary material change is the establishment of exclusive jurisdiction in the United States District Courts for the District of Delaware and the District of Massachusetts for resolving any action asserting a claim arising under the Securities Act of 1933.
Guidance, Outlook, and Risks
The filing contains no management commentary, financial guidance, or outlook. The only risk-related disclosure is the procedural change regarding the venue for legal claims under the Securities Act of 1933.
Key Facts for Investor Verification
- The Company has amended its bylaws to restrict the venue for Securities Act of 1933 claims to federal courts in Delaware and Massachusetts.
- The full text of the Second Amended and Restated Bylaws is available as Exhibit 3.1 to this filing.
- No financial performance data or operational updates are included in this specific report.